People living with HIV who have a longer duration of
detectable viral load and those with low CD4 cell counts have a higher
likelihood of developing liver cancer in the absence of advanced fibrosis,
according to a study presented at the Conference on Retroviruses and
Opportunistic Infections (CROI 2019)
last week, in Seattle.

Since the advent of effective
antiretroviral therapy, liver disease has become a leading cause of morbidity
and mortality among people living with HIV. Over years or decades, chronic hepatitis
B or C virus (HBV or HCV) infection, heavy alcohol use, fatty liver disease and
other causes of liver injury can lead to development of advanced fibrosis (build-up
of scar tissue), cirrhosis (severe scarring) and hepatocellular carcinoma
(HCC), the most common type of primary liver cancer.

The incidence of liver cancer among
people with HIV has quadrupled since 1996 and HIV-positive people have about a
fourfold higher risk of developing HCC compared with the HIV-negative general population,
Dr Jessie Torgersen of the University of Pennsylvania Perelman
School of Medicine noted as background. But the causes of this disparity remain unknown.

Torgersen and colleagues conducted a
retrospective cohort study to learn more about the influence of HIV viral load,
duration of viraemia and CD4 cell count on the incidence of liver cancer, and
whether this varies by cirrhosis status.

The researchers analysed electronic
medical records of participants in the Veterans Aging Cohort Study, an ongoing
study of HIV-positive US veterans, who had available viral load and CD4 count
measurements and at least six months of follow-up between 1999 and 2015. Those
with pre-existing HCC were excluded. As a measure of liver fibrosis, they used the
non-invasive Fibrosis-4 (FIB-4) index, which incorporates patient age, platelet count, and
alanine aminotransferase (ALT) and aspartate aminotransferase (AST) liver enzyme levels; scores above 3.25 suggest advanced fibrosis or
cirrhosis. 

The analysis included 2497 people (8%) with
advanced fibrosis or cirrhosis and 29,836 with absent, mild or moderate
fibrosis. Almost all were men, as is typical of a veterans cohort.

People with advanced liver disease had a
higher median age (50 vs 46 years) and were more likely to have HBV (10 vs 5%),
HCV (59 vs 30%) and alcohol-related diagnoses (47 vs 29%). They were also more
likely to have HIV viral load above 500 copies/ml (63 vs 56%) and a CD4 count
below 200 cells/mm3 (39 vs 26%).

During follow-up, a total of 278 people
were diagnosed with liver cancer. In this HIV-positive cohort, 43% of those who
developed HCC did not have advanced fibrosis or cirrhosis – much higher than
the approximately 13% of people who develop HCC in the absence of cirrhosis in
the HIV-negative general population.

As expected, HBV or HCV co-infection was associated
with a higher likelihood of developing liver cancer at any fibrosis level. People with HCV were over six times more likely to
develop HCC regardless of fibrosis status. Among those with advanced fibrosis
or cirrhosis, people with HBV were over twice as likely to develop HCC, while
among those without advanced fibrosis, HBV was associated with nearly a
fivefold higher risk.

Among people with advanced fibrosis or
cirrhosis, HIV viral load and CD4 count had no significant effect on liver
cancer risk. But among those without extensive fibrosis, having a higher viral load was associated with a 24% greater HCC
risk and having HIV RNA 500 copies/ml for a year or more was associated
with a 57% higher incidence. Further, those with a CD4 count below 200 cells/mm3
had 58% and 78% higher risk in two different models.

These findings indicate that risk
factors for HCC in HIV-positive people vary by baseline fibrosis, the
researchers concluded. While HBV and HCV increased HCC risk in both FIB-4
groups, in those without advanced fibrosis or cirrhosis, HIV viraemia and low
CD4 count were also important. They
added that this study provides the “strongest evidence to date” that
HIV viraemia and low CD4 count contribute to risk of HCC.